News
19.08.2021

Cromos Pharma committed to patient centricity in clinical trials

Over the last few years, patient centricity has moved from buzzword to an imperative. Sponsors are now increasingly willing to offer a patient centric approach to studies. However, there remains some confusion over what this means and how to implement it. In this article Cromos Pharma looks at some of the strategies that can be employed to promote patient centricity.

What is patient centricity?

The roots of patient centric clinical research come from the patient advocacy movement. For several years, individual patients and representative groups have argued for greater consideration and protection of patients in the drug development process. Put simply patient centricity means putting the patient at the heart of clinical research from outset to endpoint. This means patient involvement in study design, including patient perspectives on location, monitoring and evaluation. It means creating opportunities for meaningful engagement throughout the clinical trial process for patients and reducing the burden on patients and their caregivers.

What are the benefits?

The benefits of adopting a patient centric approach are numerous and varied. For the patient it creates as sense of ownership and involvement in clinical research rather than being a “guinea pig”[i]. It may also reduce the burden on patient participants in terms of travel and time. For the sponsor adopting a patient centric approach can help increase patient recruitment and retention and improve data quality. Meaningful engagement with patient groups can also promote greater diversity in studies attracting hard to reach patient populations[ii]

How to take a patient centric approach

A 2020 report by Deloitte identified four pillars that should form the foundation for patient centric clinical research:

  1. Identify concrete objectives around incorporating the patient perspective into  different processes throughout the life cycle and operationalize them.
  2. Track progress toward delivering key performance indicators (KPIs) and return on investment (ROI).
  3. Harness digital and data analytics opportunities to engage the patient and collect data on patient outcomes as well as their unmet needs.
  4. Form deeper collaborations within the industry, with advocacy groups, and clinicians[iii].

Bringing clinical trials to patients

The COVID-19 pandemic resulted in an acceleration of the trend towards decentralized clinical trials and remote monitoring as patients were unable to travel to study sites. Undoubtedly, leveraging digital technologies is a vital part of delivering on the promise of patient centricity. These tools allow us to bring the clinical trial directly to the patient and play an important part in reducing the burden of participation. Digital technologies can also be used to improve the patient experience in other ways for example simplifying and making the informed consent process better. 

Cromos Pharma and patient centricity

For Cromos Pharma, patients have always been at the centre of what we do and how we do it. We understand the important role the clinical research organization (CRO) plays in promoting patent centricity in clinical trials. As an international CRO, patient centric clinical research involves creating meaningful engagement with patients throughout the entire trial from design to execution. 

We aim to understand what the patient wants before, during and after the trial. We can address key challenges around patient recruitment by putting forward methods to identify, engage and support patients. By understanding our patients, we can assess how best to reduce the burden of participation e.g., how many site visits are preferrable, how far are patients willing to travel and what do they expect from their experience. We can identify patient-specific concerns that have an impact on recruitment, compliance, and retention. Here are some of the key elements we use to inform our approach:

  • Patient centricity at the heart of all we do: From CEO to junior CRA we know that patients are the most important part of our work. 
  • Understanding the individual patient’s experience: From the number of hospital visits to number of blood draws, understanding how each part of the clinical trial process affects each patient is key to designing a better patient experience.
  • Using technology to improve the trial experience: Being patient-centric means evolving processes alongside technological developments. This means upskilling staff, adapting to new ways of working and implementing technologies to increase engagement with patients.
  • Providing clear information to patients: Clear communication is central to improving the trial experience. This means looking at documentation to ensure it presents information in an accessible manner. It also means moving towards multimedia content and forms of eConsent.

Patient centricity is here to stay, and Cromos Pharma is committed to continuing to develop ways to improve the patient experience in clinical trials. Email us at bd@cromospharma.com today to find our how we can support your next clinical project.

References:


[i] https://innovations.bmj.com/content/3/2/76


[ii] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4504054/


[iii] https://www2.deloitte.com/us/en/insights/industry/life-sciences/patient-centricity.html



Other News:
news

Connect with us at DIA Europe and BIO-Europe this March

Cromos Pharma is delighted to be taking part in the upcoming DIA Europe conference (15 – 19 March 2021) and BIO-Europe Spring (22-25 March 2021).

 

15.02.2021
news

International Women and Girls in Science Day

February 11th is International Women and Girls in Science Day. A joint UNESCO and UN-Women initiative, it aims to promote the role of #WomenInScience and to challenge some of the barriers to girls pursuing a career in science.

11.02.2021
news

Top 5 reasons to locate your next clinical trial in Hungary

Discover some of the reasons why you should consider Hungary as a location for your next clinical trial.
09.02.2021
news

Cromos Pharma offers EU Legal Representative Service

Are you a sponsor seeking to conduct clinical trials in the European Union but do not have a registered office in the European Economic AreaIf so, in order to comply with the European Union Clinical Trial Directive, you are required to work with a Legal Representative registered in an EEA country.

04.02.2021
news

World Cancer Day 2021: Cromos Pharma is committed to supporting clinical research to make cancer breakthroughs

Each 4th February, #WorldCancerDay aims to raise awareness of the global personal, social and economic burden of cancer. World Cancer Day was established in Paris at the first World Cancer Summit in 2000.

 


04.02.2021
news

European Medicines Agency: Approvals January 2021

The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) recommended 13 new medications for approval and three therapeutic indication extensions in its January 2021 meeting.
31.01.2021
news

Upcoming EU drug/device legislation: What you need to know

Zsolt Kocsis, Cromos Pharma's Head of EU Operations explores some of the upcoming changes to EU legislation in relation to drug development and medical devices. 
25.01.2021
news

Reaping the benefits of a Euro-Australian collaboration for biotechs: save on costs and time

Cromos Pharma CEO Dr Vlad Bogin is joined by Avance Clinical's CEO Yvonne Lungershausen to discuss some of the benefits available to biotechs by availing of a joint initiative that combines Australian tax benefits for clinical research with exceptional patient recruitment and retention in Eastern European markets.
24.01.2021
news

Clinical trials in the time of COVID: Risks, mitigation and lessons learned

Clinical trials in the time of COVID: Risks, mitigation and lessons learned presented by Stephanie Finnegan, COO Cromos PharmaIn this presentation she looks at risks, how to mitigate crisis management, and what the sector has learned since being forced into some major changes due to COVID-19. 

24.01.2021
news

Clinical trials: how to enroll on time, stay on budget and not compromise data quality

Stephanie Finnegan, COO of Cromos Pharma delivers key insights into how to maintain study and data integrity when facing cost and time constraints. When time and money is of the essence how can you achieve patient recruitment targets? 
23.01.2021
news

Global vaccine rollout underway as COVID-19 cases surge

As 2021 begins, many countries are grappling with a renewed surge of COVID-19 infections necessitating further public health restrictions putting more pressure on health systems, societies and global economies.  The task of rolling out approved vaccines is increasingly urgent. Almost 16 million doses of COVID-19 vaccines have been administered to date in 37 countries worldwide according to data compiled by Bloomberg ( updated 7 Jan 2021). 

07.01.2021
news

JP Morgan Healthcare Conference: Virtual Booth and Daily Presentations

We have been meeting you at the JP Morgan Healthcare Conference for the past 11 years and there is no way we are going to break with this tradition. Meet us at the CROMOS PHARMA VIRTUAL BOOTH January 11th through 14th from 8 am to 5 pm(PST). Learn about some of the most vital issues in clinical research by attending our daily presentations or stop by anytime for a chat.


01.01.2021
news

Seasons Greetings from Cromos Pharma

Seasons Greetings from everyone at Cromos Pharma. Watch our holiday video here>>
22.12.2020
news

Watch: The benefits of Cromos Pharma and Avance Clinical's biotech initiative

In October we launched an exciting collaboration with Avance Clinical to offer biotechs a scalable clinical trials solution. The collaboration allows biotechs to quickly start their pre-IND early phase studies in Australia, then expand to Central/Eastern Europe to access the large patient populations for their Phase 2 and 3 studies. In this new video you can learn more about the benefits of this initiative.


08.12.2020
news

World AIDS Day 2020: Remarkable progress but the fight continues

Tuesday 1 December marked World AIDS Day 2020. Although throughout this year our focus has been on the coronavirus pandemic, World AIDS Day is an opportunity to reflect on another pandemic where a virus passed from animals to humans with devastating consequences. To date 77 million people worldwide have been infected with HIV. In spite of innovative new treatments 35 million people have died from the virus. 

01.12.2020
news

Thanksgiving Greetings

Thanksgiving Greetings from everyone at Cromos Pharma. Watch our video here.
20.11.2020
news

World Pancreatic Cancer Awareness Day 2020

Thursday 19 November 2020 is World Pancreatic Cancer Awareness Day. Here at Cromos Pharma we are proud to play our part in supporting clinical trials aimed at finding better treatments for pancreatic cancers. 

19.11.2020
news

FDA Offers Guidance to Enhance Diversity in Clinical Trials

The FDA released a statement (9 November 2020) outlining its commitment to promoting greater diversity in medical product development and issuing a new guidance document outlining the agency's thinking on encouraging greater inclusivity “Enhancing the Diversity of Clinical Trial Populations--Eligibility Criteria, Enrollment Practices, and Trial Designs,”
12.11.2020
news

Cromos Pharma and Avance Clinical share details of innovative collaboration at BIO-Europe 2020

Cromos Pharma and Avance Clinical announced details of their innovative collaboration to offer biotechs scalable clinical trial solutions at BIO-Europe 2020.
28.10.2020
news

Orphan Drugs Market to Reach USD 340.84 Billion by 2027

The global orphan drugs market size is projected to reach USD 340.84 billion by the end of 2027. Increasing number of regulatory approvals will have a positive impact on the growth of the overall market in the coming years according to a new report from Fortune Business Insights
26.10.2020
news

Cromos Pharma and Avance Clinical launch scalable clinical trial solution for biotech

Cromos Pharma is delighted to announce a new collaboration with Avance Clinical providing a scalable clinical trial solution for biotech.
08.10.2020
news

Video: Cromos Pharma and Avance Clinical Collaboration

Cromos Pharma and Avance Clinical are joining forces to offer a scalable clinical trial solution for biotechs. Watch the video to find out more>>
08.10.2020
news

Alzheimer's Awareness Month: Q&A with Dr Sabina Brennan

September is World Alzheimer’s Month. Alzheimer’s Disease (AD) is the most well-known form of dementia. Dementia is the collective name for progressive brain conditions affecting memory, thinking, behavior and emotions. Dementia affects almost 50 million people worldwide. While aging is a major risk factor for dementia, it also affects people under 65 years. To mark Alzheimer’s Awareness Month (Sept 2020) we sat down with leading psychologist, neuroscientist and best-selling author Dr Sabina Brennan. Dr Brennan is a brain health expert who has advised Irish and UK governments on policies relating to aging and dementia.  She is the Irish national representative on the Medical and Scientific Advisory Panel for Alzheimer’s Disease International.
28.09.2020
news

Watch Webinar: Where in the world should I locate my pivotal clinical trial?

If you missed the live webinar “Where in the world should I locate my pivotal clinical trial?” you can now watch the recording by clicking hereThe webinar hosted by the Society of Physician Entrepreneurs (SoPE) and Workforce Genetics features Cromos Pharma's CEO Vlad Bogin, M.D, FACP. 


24.09.2020
news

Watch our video: Navigating an era of uncertainty

We are pleased to share with you our new video Cromos Pharma: Helping to navigate an era of uncertainty.

02.09.2020
news

Webinar: Where in the world should I locate my pivotal clinical trial?

01.09.2020
news

EU cancer estimates for 2020 reveal 2.7 million new cases

The European Joint Research Council released its 2020 burden of cancer estimates on 22 July, 2020. The report revealed The cancer burden is estimated to have risen to 2.7 million new cases (all types, excluding non-melanoma skin cancer) and 1.3 million deaths in 2020. Female breast cancer remains the most commonly diagnosed.
26.07.2020
news

FDA proposes new rule on reporting requirements to support Right to Try

On July 23, the U.S. Food and Drug Administration (FDA) announced a new proposed rule that would require sponsors and manufacturers who provide an ‘‘eligible investigational drug’’ under the Right to Try Act to submit an annual summary of such use to FDA.
26.07.2020
news

European medicines agencies launch public consultation on joint strategy

The European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) have developed a joint strategy for the next five years. It was released for a two-month public consultation period on 6, July, 2020.
14.07.2020
news

Two new reports find impacts of COVID-19 on clinical trials easing slightly

Two new reports released by GlobalData Healthcare and Medidata find evidence of COVID-19 impacts on clinical trials easing slightly. 
13.07.2020
news

Risk Based Monitoring- a data-centric approach to monitoring

In this Insights@CromosPharma article our Chief Operating Officer Stephanie Finnegan explores the role of Risk Based Monitoring (RBM) in clinical trials, how it has been utilized in response to the current coronavirus pandemic, and how the experience may shape the industry's approach to RBM in the future.
30.06.2020
news

Cromos Pharma Recruits over 300 Patients in Under Two Months into a COVID-19 Clinical Trial

Cromos Pharma, an international CRO, is pleased to announce unprecedented recruitment in a phase IIb trial in patients with moderate to severe COVID-19 infection.
18.06.2020
news

Connect with Cromos Pharma at BIO Digital 2020

Cromos Pharma is delighted to be participating in BIO Digital 2020, June 8-12 2020. 
02.06.2020